Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Havn Life Sciences Inc (OP: HAVLF )

0.0052 UNCHANGED
Last Price Updated: 11:40 AM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Havn Life Sciences Inc

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance
Biotech psychedelics company HAVN Life Sciences Inc. (OTC: HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean (“ABO”), previously announced on July... 
Via Benzinga
Learn About HAVN Life's New Shares Consolidation, What Changes And What Remains
A key player in the biotech-meets-psychedelics space, HAVN Life Sciences Inc. 
Via Benzinga
HAVN Life Sciences & Optimi Health Corp Announce Supply Agreements, Here Are The Details
Two publicly traded psychedelics companies announced supply agreements. HAVN Life Sciences (OTC: HAVLF) will provide mental health clinic MPB Group Inc. with psilocybin-containing mushrooms for its... 
Via Benzinga
Psyched: Cathie Wood Invests In Psychedelics Co ATAI, Bill Approved in Utah, AI Startup To 'Design States Of Mind'
The psychedelics sector received its latest sign of acceptance from Wall Street with famed investor Cathie Wood taking a position ... 
Via Benzinga
Amanita Muscaria: A Legal Psychoactive Mushroom With Potential Therapeutic Effects
Amanita Muscaria is an understudied species of psychoactive mushroom that’s as commonplace as it is misunderstood. The iconic red-c... 
Via Benzinga
HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function,... 
Via Benzinga
Havn Life Buys Subscription-Based Functional Mushroom Co. With Significant US Consumer Base
Biotech company Havn Life Sciences Inc. (CSE:HAVN) (OTC: HAVLF) is purchasing functional mushroom wellness brand Spore Life Sciences Inc. The Deal Details Under the deal... 
Via Benzinga
HAVN Life Successfully Exports Naturally Derived Psilocybin From Its Jamaica Facility Into Canada
Demonstrating the integrity of its supply chain from Jamaica into Canada, biotechnology company HAVN Life Sciences (OTCPK: HAVLF) achieved a milestone with... 
Via Benzinga
Former Tilray CEO Joins Psychedelics Company
More big names in cannabis are switching to psychedelics. Greg Engel, former CEO of Tilray (NASDAQ: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
The Week In Psychedelics: 
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Last Week In Psychedelics: 
Via Benzinga
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Contents 
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Last week in Psychedelics: 
Via Benzinga
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
HAVN Life is Looking for a Safe Haven to Mental Health Through Psychedelic Medicine
Most companies' success stories come as a result of wanting to accomplish a greater purpose. For HAVN Life Sciences Inc. (CSE: HAVN) (OTC PINK: HAVLF) (FSE: 5NP) CEO Tim Moore... 
Via Benzinga
Psychedelic Drug Stocks Index -21% In May; Now -25% YTD
46 psychedelic drug stocks now trade on the various North American stock exchanges and the 11 with the largest market capitalizations make up the Pure-Play Psychedelic Drug Stocks Index. 
Via Talk Markets
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa... 
Via Benzinga
Exposures Product Safety
Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound... 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.